Bausch + Lomb to Present New Scientific Data at BCLA 2025 Congress

VAUGHAN, Ontario, May 28, 2025 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced nine scientific presentations during the British Contact Lens Association (BCLA) Congress, taking place in Birmingham, UK, June 5-7, 2025. The company will also sponsor several educational events.

Scientific presentations will feature an assessment of multi-country patient and eye care professional satisfaction data for Bausch + Lomb Ultra® One Day (kalifilcon A) contact lenses (known as Bausch + Lomb INFUSE® in the United States), Bausch + Lomb ULTRA® (samfilcon A) contact lenses with Biotrue® Hydration Plus Multi-Purpose Solution, and Zenlens® scleral lenses. In addition, clinical insights evaluating Artelac Complete® Preservative Free Lubricating Eye Drops and Biotrue® Hydration Boost Lubricant Eye Drops for dry eyes will be highlighted. 

See below for the complete list of Bausch + Lomb scientific presentations and events. 

Paper Presentations 

  • “Clinical Outcomes with an HOA Correcting Scleral Lens for Keratoconus.” Jedlicka J. 

Poster Presentations 

  • “A Multi-Country Assessment of Eyecare Practitioner Clinical Experience and Satisfaction with a Custom Scleral Lens System.” Gildea C. et al. 
  • “A Multi-Country Assessment of Real-World Clinical Outcomes with a Custom Scleral Lens System.” Gildea C. et al. 
  • “Analysis of Real-World Clinical Experience with a Custom Scleral Lens System Utilizing Bi-Elevation to Address Uneven Limbal Clearance.” Messer B. et al. 
  • “Eyecare Provider Perspectives on the Treatment Landscape for Conjunctival Hyperaemia in Europe.” Borges JS et al. 
  • “Fitting Success Rates with a Novel Daily Disposable Multifocal Contact Lens: A Multicenter Clinical Study.” Holland Z. et al. 
  • “Patient and Eyecare Professional Satisfaction with Kalifilcon a Spherical Daily Disposable Contact Lenses for Existing Planned Replacement Soft Contact Lens Wearers.” Patel K.
  • “Real-world Patient Experience with Samfilcon a Contact Lenses in Combination with a Unique Multi-Purpose Solution Containing Hyaluronan.” Wolffsohn J. et al. 
  • “A Multicentre Clinical Study of Two Preservative-Free Artificial Tears with Sodium Hyaluronate for the Treatment of Dry Eye.” Labetoulle M. et al. 

Thursday, June 5, 2025 

Success with Contact Lens Wear – Addressing Dryness and Ocular Surface Homeostasis 

  • 11:30-13:00 BST; The ICC, Hall 8B 
  • Speakers: Jennifer Craig, Sarah Farrant, Fiona Stapleton and Keyur Patel  

Focus Forward: Changing Practices in Eye Care and Contact Lens Innovations  

  • 15:30–16:30 BST; The ICC, Hall 1 
  • Speakers: James Wolffsohn, Byki Huntjens, Brooke Messer and Mohamed Yassine 

Friday, June 6, 2025 

From A to Z: Take the Path to Specialty Lens Simplicity with ARISE™ Ortho-K Lenses and Zenlens Scleral Lenses from Bausch + Lomb 

  • 7:30-8:30 BST; The ICC, Hall 8B 

Future of Vision Care: Innovation, Technology and Real-World Impact 

  • 12:30-13:00 BST; The ICC, Hall 1 
  • Speakers: Mohamed Yassine, Byki Huntjens and Cian Gildea 

A Special Embrace: How Specialty Lenses can Elevate Patient Care and Set Your Office Apart 

  • 15:30-17:00 BST; The ICC, Hall 8A 
  • Speakers: Jason Jedlicka and Brooke Messer  

###

Important Safety Information for Zenlens  

WARNINGS: 

Patients should be advised of the following warnings pertaining to contact lens wear: 

  • Problems with contact lenses and lens care products could result in serious injury to the eye. It is essential that patients follow their eyecare practitioner’s directions and all labeling instructions for proper use of lenses and lens care products, including the lens case. Eye problems, including corneal ulcers, can develop rapidly and lead to loss of vision. 
  • Daily wear lenses are not indicated for overnight wear, and patients should be instructed not to wear lenses while sleeping. 
  • Clinical studies have shown that the risk of serious adverse reactions is increased when daily wear lenses are worn overnight. 
  • Studies have shown that contact lens wearers who are smokers have a higher incidence of adverse reactions than nonsmokers. 
  • If a patient experiences eye discomfort, excessive tearing, vision changes, or redness of the eye, the patient should be instructed to immediately remove lenses and promptly contact his or her eyecare practitioner. 

CONTRAINDICATIONS: 

Do not use when any of the following conditions exist: 

  • Acute or subacute inflammation or infection of the anterior chamber of the eye 
  • Any eye disease, injury or abnormality, other than keratoconus, PMD, that affects the cornea, conjunctiva or eyelids 
  • Severe insufficiency of lacrimal secretion (dry eye) 
  • Corneal hypoesthesia (reduced sensitivity), if not aphakic 
  • Any systemic disease that may affect the eye or be exaggerated by wearing contact lenses 
  • Allergic reactions of ocular surfaces or adnexa that may be induced or exaggerated by wearing contact lenses or using contact lens solutions 
  • Allergy to any ingredient in a solution which is to be used to care for contact lenses 
  • Any active corneal infection (bacterial, fungal or viral) 
  • Red or irritated eyes 

ADVERSE EFFECTS: 

The following problems may occur with the use of contact lenses: 

  • Eyes stinging, burning, itching, irritation or other eye pain 
  • Comfort is less than when the lens was first placed on the eye 
  • Feeling of something in the eye such as a foreign body, scratched area 
  • Excessive watering (tearing) of the eye 
  • Unusual eye secretions Redness of the eyes 
  • Reduced sharpness of vision (poor visual acuity) 
  • Blurred vision, rainbows, or halos around objects 
  • Sensitivity to light (photophobia) 
  • Dry eyes 

Important Safety Information for Arise™ Orthokeratology Lens System 

INDICATIONS FOR USE 

Boston Orthokeratology (oprifocon A) shaping lenses for overnight wear are indicated for use in the reduction of myopic refractive error in non-diseased eyes. The lenses are indicated for overnight wear as part of the Bausch + Lomb Vision Shaping Treatment VST® process for the temporary reduction of myopia up to 5.00 diopters with eyes having astigmatism up to 1.50 diopters. The lenses may only be disinfected using a chemical disinfection system. 

SAFETY INFORMATION CONTRAINDICATIONS 

DO NOT USE the Boston Orthokeratology (oprifocon A) shaping lenses when any of the following conditions exist: 

  • Acute and sub-acute inflammations or infection of the anterior chamber of the eye 
  • Any eye disease, injury, or abnormality that affects the cornea, conjunctiva, or eyelids 
  • Severe insufficiency of tears (dry eyes) 
  • Corneal hypoesthesia (reduced corneal sensitivity) 
  • Any systemic disease which may affect the eye or be exacerbated by wearing contact lenses 
  • Allergic reactions of ocular surfaces or adnexa which may be induced or exaggerated by wearing contact lenses or use of contact lens solutions 
  • Allergy to any ingredient, such as mercury or thimerosal, in a solution which is to be used to care for your Boston Orthokeratology (oprifocon A) shaping lenses 
  • Any active corneal infection (bacterial, fungal, or viral) 
  • If eyes become red or irritated 

WARNINGS 

The risk of ulcerative keratitis has been shown to be greater among wearers of extended wear lenses than among wearers of daily wear lenses. The risk among extended wear use users increases the number of consecutive days that lenses are worn between removals, beginning with the first overnight use. Smoking increases the risk of ulcerative keratitis for contact lens wearers. Wearing the lenses continuously (extended wear) presents increased risk, which increases with the number of consecutive days the lenses are worn between removals. Although the safety risks of overnight wear with removal upon wakening may not be as great as with extended wear, there is still increased risk beginning with the first overnight period.

PRECAUTIONS 

When selecting an appropriate lens design and parameters, the eye care practitioner should consider all factors that affect lens performance and the patient’s ocular health; including oxygen permeability, wettability, central and peripheral thickness, and optic zone diameter. 

ADVERSE EVENTS 

A total of 378 eyes (191 patients) were enrolled in a clinical study. There were twelve significant lens-related adverse events reported in ten subjects. All eyes that showed acuity reductions were documented as returning to normal vision, except two eyes of one subject with severe corneal staining that showed ≥2 lines loss of BSCVA. The return to pre-treatment VA was not recorded for this subject, although the subject returned to soft contact lens wear and verbally reported that vision was normal. All adverse events resolved without further complications. A separate clinical study evaluated the effect of non-spherical (toric) peripheral curves on 45 astigmatic patients who were orthokeratology lens-naïve. Among the dispensed subjects, no significant adverse events were reported. 

ATTENTION: Refer to the package insert for a complete listing of indications, warnings and precautions, clinical trial information, etc. 

CAUTION: Federal (USA) law restricts this device to the sale by, or on the order of a licensed practitioner. 

About Bausch + Lomb 

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube. 

Media Contact: 
Kristy Marks
[email protected]
(908) 927-0683 
© 2025 Bausch + Lomb.
MTB.0331.USA.25

Back to Press Releases